RIPK1 mediates a disease-associated microglial respons

Proceedings of the National Academy of Sciences of the Unite
114, E8788-E8797
DOI: 10.1073/pnas.1714175114

Citation Report

#	Article	IF	Citations
1	RIPK1 promotes inflammation and Î²-amyloid accumulation in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10813-10814.	3.3	16
2	PELI1 functions as a dual modulator of necroptosis and apoptosis by regulating ubiquitination of RIPK1 and mRNA levels of c-FLIP. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 11944-11949.	3.3	83
3	Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy. Frontiers in Neuroscience, 2017, 11, 680.	1.4	108
4	Practical considerations for choosing a mouse model of Alzheimerâ€™s disease. Molecular Neurodegeneration, 2017, 12, 89.	4.4	305
5	MK2â€“TNFâ€“Signaling Comes Full Circle. Trends in Biochemical Sciences, 2018, 43, 170-179.	3.7	37
6	Necroptosis promotes cell-autonomous activation of proinflammatory cytokine gene expression. Cell Death and Disease, 2018, 9, 500.	2.7	141
7	Necroptosis in development and diseases. Genes and Development, 2018, 32, 327-340.	2.7	270
8	Kinase-Based Taming of Brain Microglia Toward Disease-Modifying Therapy. Frontiers in Cellular Neuroscience, 2018, 12, 474.	1.8	10
9	Distinct Microglial Responses in Two Transgenic Murine Models of TAU Pathology. Frontiers in Cellular Neuroscience, 2018, 12, 421.	1.8	23
10	Positive Feedback Loops in Alzheimerâ€™s Disease: The Alzheimerâ€™s Feedback Hypothesis. Journal of Alzheimer's Disease, 2018, 66, 25-36.	1.2	32
11	TREM2 â€” a key player in microglial biology and Alzheimer disease. Nature Reviews Neurology, 2018, 14, 667-675.	4.9	396
12	Alzheimerâ€™s disease (AD) therapeutics â€“ 2: Beyond amyloid â€“ Re-defining AD and its causality to discover effective therapeutics. Biochemical Pharmacology, 2018, 158, 376-401.	2.0	24
13	Inhibiting RIP1 Improves Chronic Stress-Induced Cognitive Impairments in D-Galactose-Induced Aging Mice. Frontiers in Behavioral Neuroscience, 2018, 12, 234.	1.0	18
14	Clinical PET Imaging of Microglial Activation: Implications for Microglial Therapeutics in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 314.	1.7	60
15	Cell-autonomous requirement of TDP-43, an ALS/FTD signature protein, for oligodendrocyte survival and myelination. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10941-E10950.	3.3	68
16	Better Together: A Hybrid Amyloid Signals Necroptosis. Cell, 2018, 173, 1068-1070.	13.5	7
17	Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration. Cell, 2018, 173, 1073-1081.	13.5	765
18	Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau. Journal of Experimental Medicine, 2018, 215, 2235-2245.	4.2	167

#	Article	IF	Citations
19	The transcription factor C/EBP Î± controls the role of cystatin F during the differentiation of monocytes to macrophages. European Journal of Cell Biology, 2018, 97, 463-473.	1.6	16
20	Inhibiting RIPK1 Limits Neuroinflammation and Alleviates Postoperative Cognitive Impairments in D-Galactose-Induced Aged Mice. Frontiers in Behavioral Neuroscience, 2018, 12, 138.	1.0	22
21	The emerging roles of protein homeostasisâ€governing pathways in Alzheimer's disease. Aging Cell, 2018, 17, e12801.	3.0	88
22	TBK1 Suppresses RIPK1-Driven Apoptosis and Inflammation during Development and in Aging. Cell, 2018, 174, 1477-1491.e19.	13.5	291
23	Suppression of Presymptomatic Oxidative Stress and Inflammation in Neurodegeneration by Grape-Derived Polyphenols. Frontiers in Pharmacology, 2018, 9, 867.	1.6	29
24	RIP kinases as modulators of inflammation and immunity. Nature Immunology, 2018, 19, 912-922.	7.0	174
25	Regulation of a distinct activated RIPK1 intermediate bridging complex I and complex II in TNFÎ±-mediated apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5944-E5953.	3.3	110
26	miR-425 deficiency promotes necroptosis and dopaminergic neurodegeneration in Parkinsonâ€™s disease. Cell Death and Disease, 2019, 10, 589.	2.7	68
27	Reformulating Pro-Oxidant Microglia in Neurodegeneration. Journal of Clinical Medicine, 2019, 8, 1719.	1.0	47
28	Autocatalytic amplification of Alzheimer-associated AÎ²42 peptide aggregation in human cerebrospinal fluid. Communications Biology, 2019, 2, 365.	2.0	46
29	Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors. Cancer Cell, 2019, 36, 597-612.e8.	7.7	100
30	Alzheimerâ€™s Disease Progression in the 5Ã—FAD Mouse Captured with a Multiplex Gene Expression Array. Journal of Alzheimer's Disease, 2019, 72, 1177-1191.	1.2	7
31	The potential role of necroptosis in inflammaging and aging. GeroScience, 2019, 41, 795-811.	2.1	81
32	Current translational potential and underlying molecular mechanisms of necroptosis. Cell Death and Disease, 2019, 10, 860.	2.7	69
33	Mechanisms of Neuronal Death in the Cerebral Cortex during Aging and Development of Alzheimerâ€™s Disease-Like Pathology in Rats. International Journal of Molecular Sciences, 2019, 20, 5632.	1.8	32
34	A rare functional variant of SHARPIN attenuates the inflammatory response and associates with increased risk of late-onset Alzheimerâ€™s disease. Molecular Medicine, 2019, 25, 20.	1.9	33
35	Neuroprotection in Alzheimer Disease. Springer Protocols, 2019, , 465-585.	0.1	1
36	Profile of Junying Yuan. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 201906915.	3.3	0

#	Article	IF	Citations
37	Targeting RIPK1 for the treatment of human diseases. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9714-9722.	3.3	258
38	Leveraging the interplay of nanotechnology and neuroscience: Designing new avenues for treating central nervous system disorders. Advanced Drug Delivery Reviews, 2019, 148, 181-203.	6.6	25
39	Nanowired delivery of cerebrolysin with neprilysin and p-Tau antibodies induces superior neuroprotection in Alzheimer's disease. Progress in Brain Research, 2019, 245, 145-200.	0.9	30
40	Molecular Insights into the Mechanism of Necroptosis: The Necrosome as a Potential Therapeutic Target. Cells, 2019, 8, 1486.	1.8	112
41	The clinical relevance of necroinflammationâ€"highlighting the importance of acute kidney injury and the adrenal glands. Cell Death and Differentiation, 2019, 26, 68-82.	5.0	26
42	The involvement of microglia in Alzheimer's disease: a new dog in the fight. British Journal of Pharmacology, 2019, 176, 3533-3543.	2.7	27
43	Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nature Reviews Neuroscience, 2019, 20, 19-33.	4.9	562
44	Crashing the computer: apoptosis vs. necroptosis in neuroinflammation. Cell Death and Differentiation, 2019, 26, 41-52.	5.0	97
45	The Evolving Dialogue of Microglia and Neurons in Alzheimerâ€™s Disease: Microglia as Necessary Transducers of Pathology. Neuroscience, 2019, 405, 24-34.	1.1	60
46	Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives. Journal of Medicinal Chemistry, 2020, 63, 1490-1510.	2.9	56
47	Multitasking Kinase RIPK1 Regulates Cell Death and Inflammation. Cold Spring Harbor Perspectives in Biology, 2020, 12, a036368.	2.3	56
48	<scp>DNL</scp>104, a Centrally Penetrant <scp>RIPK</scp>1 Inhibitor, Inhibits <scp>RIP</scp>1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2020, 107, 406-414.	2.3	48
49	Fragile X mental retardation protein protects against tumour necrosis factor-mediated cell death and liver injury. Gut, 2020, 69, 133-145.	6.1	14
50	BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease. Medicinal Research Reviews, 2020, 40, 339-384.	5.0	177
51	Cell Death and Neurodegeneration. Cold Spring Harbor Perspectives in Biology, 2020, 12, a036434.	2.3	60
52	Sphingolipids in Alzheimer's disease, how can we target them?. Advanced Drug Delivery Reviews, 2020, 159, 214-231.	6.6	53
53	Brain Parenchymal and Extraparenchymal Macrophages in Development, Homeostasis, and Disease. Journal of Immunology, 2020, 204, 294-305.	0.4	40
54	Mitochondria-targeted TPP-MoS2 with dual enzyme activity provides efficient neuroprotection through M1/M2 microglial polarization in an Alzheimer's disease model. Biomaterials, 2020, 232, 119752.	5.7	123

#	Article	IF	Citations
55	A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1. Nature, 2020, 577, 109-114.	13.7	163
56	An â€œAmyloidâ€² Cleanerâ€•for the Treatment of Alzheimer's Disease by Normalizing Microglial Dysfunction. Advanced Science, 2020, 7, 1901555.	5.6	54
57	Mechanisms of Cell Death. , 2020, , 135-153.		0
58	Hemorrhage Associated Mechanisms of Neuroinflammation in Experimental Traumatic Brain Injury. Journal of NeuroImmune Pharmacology, 2020, 15, 181-195.	2.1	10
59	Necrosome complex detected in granulovacuolar degeneration is associated with neuronal loss in Alzheimerâ€™s disease. Acta Neuropathologica, 2020, 139, 463-484.	3.9	91
60	Necroptosis in the Pathophysiology of Disease. American Journal of Pathology, 2020, 190, 272-285.	1.9	174
61	Agonist-induced functional analysis and cell sorting associated with single-cell transcriptomics characterizes cell subtypes in normal and pathological brain. Genome Research, 2020, 30, 1633-1642.	2.4	7
62	Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease. Frontiers in Aging Neuroscience, 2020, 12, 242.	1.7	28
63	Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nature Reviews Drug Discovery, 2020, 19, 553-571.	21.5	229
64	Discovery of a novel small molecule PT109 with multi-targeted effects against Alzheimer's disease in vitro and in vivo. European Journal of Pharmacology, 2020, 883, 173361.	1.7	9
65	Catalytically inactive RIP1 and RIP3 deficiency protect against acute ischemic stroke by inhibiting necroptosis and neuroinflammation. Cell Death and Disease, 2020, 11, 565.	2.7	38
66	Microglia: Agents of the CNS Pro-Inflammatory Response. Cells, 2020, 9, 1717.	1.8	174
67	Aging aggravated liver ischemia and reperfusion injury by promoting hepatocyte necroptosis in an endoplasmic reticulum stress-dependent manner. Annals of Translational Medicine, 2020, 8, 869-869.	0.7	22
68	Emerging connectivity of programmed cell death pathways and its physiological implications. Nature Reviews Molecular Cell Biology, 2020, 21, 678-695.	16.1	465
69	Microglia-targeting nanotherapeutics for neurodegenerative diseases. APL Bioengineering, 2020, 4, 030902.	3.3	49
70	The Complexity of Microglial Interactions With Innate and Adaptive Immune Cells in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2020, 12, 592359.	1.7	31
71	The Role of Chronic Inflammatory Bone and Joint Disorders in the Pathogenesis and Progression of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2020, 12, 583884.	1.7	14
72	Reduction of mNAT1/hNAT2 Contributes to Cerebral Endothelial Necroptosis and Aî² Accumulation in Alzheimerâ€™s Disease. Cell Reports, 2020, 33, 108447.	2.9	26

#	Article	IF	Citations
73	Mechanisms underlying progression in multiple sclerosis. Current Opinion in Neurology, 2020, 33, 277-285.	1.8	88
74	Molecular mechanisms of necroptosis and relevance for neurodegenerative diseases. International Review of Cell and Molecular Biology, 2020, 353, 31-82.	1.6	30
75	Apelin attenuates streptozotocin-induced learning and memory impairment by modulating necroptosis signaling pathway. International Immunopharmacology, 2020, 84, 106546.	1.7	18
76	Hepatocyte-specific TAK1 deficiency drives RIPK1 kinase-dependent inflammation to promote liver fibrosis and hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 14231-14242.	3.3	40
77	ROS-associated immune response and metabolism: a mechanistic approach with implication of various diseases. Archives of Toxicology, 2020, 94, 2293-2317.	1.9	30
78	25-Hydroxycholesterol amplifies microglial IL-1Î² production in an apoE isoform-dependent manner. Journal of Neuroinflammation, 2020, 17, 192.	3.1	57
79	DHA attenuates AÎ²-induced necroptosis through the RIPK1/RIPK3 signaling pathway in THP-1 monocytes. Biomedicine and Pharmacotherapy, 2020, 126, 110102.	2.5	17
80	Cell death and survival pathways in Alzheimer's disease: an integrative hypothesis testing approach utilizing -omic data sets. Neurobiology of Aging, 2020, 95, 15-25.	1.5	23
81	Inhibiting Necroptosis of Spermatogonial Stem Cell as a Novel Strategy for Male Fertility Preservation. Stem Cells and Development, 2020, 29, 475-487.	1.1	12
82	A Conditionally Releasable â€œDo not Eat Meâ€•CD47 Signal Facilitates Microgliaâ€Targeted Drug Delivery for the Treatment of Alzheimer's Disease. Advanced Functional Materials, 2020, 30, 1910691.	7.8	33
83	Potential of activated microglia as a source of dysregulated extracellular microRNAs contributing to neurodegeneration in amyotrophic lateral sclerosis. Journal of Neuroinflammation, 2020, 17, 135.	3.1	25
84	Autophosphorylation at serine 166 regulates RIP kinase 1-mediated cell death and inflammation. Nature Communications, 2020, 11, 1747.	5.8	85
85	Overexpressed microRNA-494 represses RIPK1 to attenuate hippocampal neuron injury in epilepsy rats by inactivating the NF-ÎºB signaling pathway. Cell Cycle, 2020, 19, 1298-1313.	1.3	14
86	Hippocampal Deficits in Amyloid-Î²-Related Rodent Models of Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2020, 14, 266.	1.4	44
87	The necroptosis pathway and its role in age-related neurodegenerative diseases: will it open up new therapeutic avenues in the next decade?. Expert Opinion on Therapeutic Targets, 2020, 24, 679-693.	1.5	13
88	IL-33-PU.1 Transcriptome Reprogramming Drives Functional State Transition and Clearance Activity of Microglia in Alzheimerâ€™s Disease. Cell Reports, 2020, 31, 107530.	2.9	65
89	Pharmacotherapy of Alzheimerâ€™s Disease: Seeking Clarity in a Time of Uncertainty. Frontiers in Pharmacology, 2020, 11, 261.	1.6	48
90	Genetic inactivation of RIP1 kinase does not ameliorate disease in a mouse model of ALS. Cell Death and Differentiation, 2021, 28, 915-931.	5.0	21

#	Article	IF	Citations
91	Novel Targets for Alzheimer's Disease: A View Beyond Amyloid. Annual Review of Medicine, 2021, 72, 15-28.	5.0	22
92	Microglia in neurodegenerative diseases. Neural Regeneration Research, 2021, 16, 270.	1.6	59
93	MicroRNA and mRNA profiling of cerebral cortex in a transgenic mouse model of Alzheimerâ€™s disease by RNA sequencing. Neural Regeneration Research, 2021, 16, 2099.	1.6	19
94	Neuroinflammation in Alzheimer's disease and beneficial action of luteolin. BioFactors, 2021, 47, 207-217.	2.6	21
95	Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases. CNS and Neurological Disorders - Drug Targets, 2021, 20, 430-450.	0.8	29
96	TREM2 Mediates Microglial Anti-Inflammatory Activations in Alzheimerâ€™s Disease: Lessons Learned from Transcriptomics. Cells, 2021, 10, 321.	1.8	25
97	Utilizing an Animal Model to Identify Brain Neurodegeneration-Related Biomarkers in Aging. International Journal of Molecular Sciences, 2021, 22, 3278.	1.8	1
98	Altered mitochondrial calcium handling and cell death by necroptosis: An emerging paradigm. Mitochondrion, 2021, 57, 47-62.	1.6	20
99	A RIPK1-regulated inflammatory microglial state in amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	36
100	The PKR/P38/RIPK1 Signaling Pathway as a Therapeutic Target in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 3136.	1.8	17
101	GLP-1 Receptor Agonist Inhibited the Activation of RIPK1 for Alleviation the Neuronal Death and Neuroinflammation in APP/PS1 Mice. International Journal of Peptide Research and Therapeutics, 2021, 27, 1699-1707.	0.9	1
102	The potential role of necroptosis in clinical diseases (Review). International Journal of Molecular Medicine, 2021, 47, .	1.8	22
103	Impact of myeloid RIPK1 gene deletion on atherogenesis in ApoE-deficient mice. Atherosclerosis, 2021, 322, 51-60.	0.4	10
104	RIP1 Perturbation Induces Chondrocyte Necroptosis and Promotes Osteoarthritis Pathogenesis via Targeting BMP7. Frontiers in Cell and Developmental Biology, 2021, 9, 638382.	1.8	22
105	RIPK1 inhibitor ameliorates the MPP+/MPTP-induced Parkinsonâ€™s disease through the ASK1/JNK signalling pathway. Brain Research, 2021, 1757, 147310.	1.1	18
106	CircRNA-ceRNA Network Revealing the Potential Regulatory Roles of CircRNA in Alzheimerâ€™s Disease Involved the cGMP-PKG Signal Pathway. Frontiers in Molecular Neuroscience, 2021, 14, 665788.	1.4	27
107	Oxidative stress and regulated cell death in Parkinsonâ€™s disease. Ageing Research Reviews, 2021, 67, 101263.	5.0	162
108	RIPK1 activation mediates neuroinflammation and disease progression in multiple sclerosis. Cell Reports, 2021, 35, 109112.	2.9	54

#	Article	IF	Citations
109	miR-335 Targets LRRK2 and Mitigates Inflammation in Parkinsonâ€™s Disease. Frontiers in Cell and Developmental Biology, 2021, 9, 661461.	1.8	18
110	Molecular mechanisms of cell death in neurological diseases. Cell Death and Differentiation, 2021, 28, 2029-2044.	5.0	268
111	Discovery of a cooperative mode of inhibiting RIPK1 kinase. Cell Discovery, 2021, 7, 41.	3.1	14
112	Cystatin F acts as a mediator of immune suppression in glioblastoma. Cellular Oncology (Dordrecht), 2021, 44, 1051-1063.	2.1	8
113	Expression of Ripk1 and DAM genes correlates with severity and progression of Krabbe disease. Human Molecular Genetics, 2021, 30, 2082-2099.	1.4	5
114	Inhibition of Smad3 in macrophages promotes AÎ² efflux from the brain and thereby ameliorates Alzheimer's pathology. Brain, Behavior, and Immunity, 2021, 95, 154-167.	2.0	7
115	Acute TBK1/IKK-Îµ Inhibition Enhances the Generation of Disease-Associated Microglia-Like Phenotype Upon Cortical Stab-Wound Injury. Frontiers in Aging Neuroscience, 2021, 13, 684171.	1.7	11
116	Fibrillar Î±-synuclein induces neurotoxic astrocyte activation via RIP kinase signaling and NF-ÎºB. Cell Death and Disease, 2021, 12, 756.	2.7	37
117	Necroptosis: A Novel Pathway in Neuroinflammation. Frontiers in Pharmacology, 2021, 12, 701564.	1.6	58
118	Therapy for Alzheimerâ€™s disease: Missing targets and functional markers?. Ageing Research Reviews, 2021, 68, 101318.	5.0	34
119	Cornel Iridoid Glycoside Ameliorated Alzheimerâ€™s Disease-Like Pathologies and Necroptosis through RIPK1/MLKL Pathway in Young and Aged SAMP8 Mice. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-11.	0.5	8
120	NEK1-mediated retromer trafficking promotes bloodâ€“brain barrier integrity by regulating glucose metabolism and RIPK1 activation. Nature Communications, 2021, 12, 4826.	5.8	20
121	Novel insights into RIPK1 as a promising target for future Alzheimerâ€™s disease treatment. , 2022, 231, 107979.		26
122	The latest information on the RIPK1 post-translational modifications and functions. Biomedicine and Pharmacotherapy, 2021, 142, 112082.	2.5	21
123	The pleiotropic roles of autophagy in Alzheimer's disease: From pathophysiology to therapy. Current Opinion in Pharmacology, 2021, 60, 149-157.	1.7	20
124	Characterizing the role of the dark kinome in neurodegenerative disease â€“ A mini review. Biochimica Et Biophysica Acta - General Subjects, 2021, 1865, 130014.	1.1	3
125	Small molecule therapeutics for neuroinflammation-mediated neurodegenerative disorders. RSC Medicinal Chemistry, 2021, 12, 871-886.	1.7	10
126	Aging-Dependent Mitophagy Dysfunction in Alzheimerâ€™s Disease. Molecular Neurobiology, 2021, 58, 2362-2378.	1.9	25

#	Article	IF	Citations
127	Comparisons of neuroinflammation, microglial activation, and degeneration of the locus coeruleus-norepinephrine system in APP/PS1 and aging mice. Journal of Neuroinflammation, 2021, 18, 10.	3.1	35
128	Transcriptional Signatures of Tau and Amyloid Neuropathology. Cell Reports, 2020, 30, 2040-2054.e5.	2.9	45
129	Autophagy regulates inflammatory programmed cell death via turnover of RHIM-domain proteins. ELife, 2019, 8, .	2.8	73
130	Stage-Dependent Impact of RIPK1 Inhibition on Atherogenesis: Dual Effects on Inflammation and Foam Cell Dynamics. Frontiers in Cardiovascular Medicine, 2021, 8, 715337.	1.1	6
131	Visualization of Receptor-Interacting Protein Kinase 1 (RIPK1) by Brain Imaging with Positron Emission Tomography. Journal of Medicinal Chemistry, 2021, 64, 15420-15428.	2.9	8
132	SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation. Cell Research, 2021, 31, 1230-1243.	5.7	62
133	Role of bioactive peptides derived from food proteins in programmed cell death to treat inflammatory diseases and cancer. Critical Reviews in Food Science and Nutrition, 2023, 63, 3664-3682.	5.4	9
134	Quantitative analysis of phosphoproteome in necroptosis reveals a role of TRIM28 phosphorylation in promoting necroptosis-induced cytokine production. Cell Death and Disease, 2021, 12, 994.	2.7	7
135	Transcriptional Signatures of Progressive Neuropathology in Transgenic Models of Tau and Amyloid Pathology. SSRN Electronic Journal, 0, , .	0.4	0
137	Receptor-Interacting Protein Kinase 1 (RIPK1) as a Potential Therapeutic Target: An Overview of Its Possible Role in the Pathogenesis of Alzheimer's Disease. Current Alzheimer Research, 2019, 16, 907-918.	0.7	10
139	Chemical Probes in Cellular Assays for Target Validation and Screening in Neurodegeneration. Chemical Biology, 2020, , 276-319.	0.1	0
140	Microglia and its Genetics in Alzheimer's Disease. Current Alzheimer Research, 2021, 18, 676-688.	0.7	10
142	Innate Immunity and Cell Death in Alzheimer's Disease. ASN Neuro, 2021, 13, 17590914211051908.	1.5	1
143	Genetic Regulation of RIPK1 and Necroptosis. Annual Review of Genetics, 2021, 55, 235-263.	3.2	28
144	A Survey of the Clinical Pipeline in Neuroscience. Bioorganic and Medicinal Chemistry Letters, 2021, 56, 128482.	1.0	0
145	Downregulating expression of OPTN elevates neuroinflammation via AIM2 inflammasome- and RIPK1-activating mechanisms in APP/PS1 transgenic mice. Journal of Neuroinflammation, 2021, 18, 281.	3.1	21
146	Innate Immunity and Cell Death in Alzheimer's Disease. ASN Neuro, 2021, 13, 175909142110519.	1.5	19
147	Design, synthesis, and evaluation of potent RIPK1 inhibitors with inÂvivo anti-inflammatory activity. European Journal of Medicinal Chemistry, 2022, 228, 114036.	2.6	9

#	Article	IF	Citations
148	Controlled decompression attenuates brain damage in a rat model of epidural extreme intracranial hypertension: Partially via inhibiting necroptosis and inflammatory response. Neurochemistry International, 2022, 153, 105257.	1.9	6
149	Synapses, Microglia, and Lipids in Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2021, 15, 778822.	1.4	10
150	Differential Regulation of Microglial Activation in Response to Different Degree of Ischemia. Frontiers in Immunology, 2022, 13, 792638.	2.2	6
151	Functional insight into LOAD-associated microglial response genes. Open Biology, 2022, 12, 210280.	1.5	5
152	IKKÎ² Alleviates Neuron Injury in Alzheimerâ€™s Disease via Regulating Autophagy and RIPK1-Mediated Necroptosis. Molecular Neurobiology, 2022, 59, 2407-2423.	1.9	3
153	SRPK2 Expression and Beta-Amyloid Accumulation Are Associated With BV2 Microglia Activation. Frontiers in Integrative Neuroscience, 2021, 15, 742377.	1.0	1
154	Roles of receptorâ€interacting protein kinase 1 in SHâ€SY5Y cells with beta amyloidâ€induced neurotoxicity. Journal of Cellular and Molecular Medicine, 2022, 26, 1434-1444.	1.6	3
155	The potent inhibitory role of suppressing TBK1 in RIPK1 associated cerebral ischemia-reperfusion injury. Brain Research, 2022, 1781, 147813.	1.1	2
156	Inhibition of RIPK1 by ZJU-37 promotes oligodendrocyte progenitor proliferation and remyelination via NF-ÎºB pathway. Cell Death Discovery, 2022, 8, 147.	2.0	4
157	Versatile nanomaterials for Alzheimer's disease: Pathogenesis inspired disease-modifying therapy. Journal of Controlled Release, 2022, 345, 38-61.	4.8	11
158	Carbamylated Erythropoietin-Fc (CEPO-Fc) ameliorates AÎ²25-35 induced neurotoxicity by modulating autophagy, apoptosis, and necroptosis in Alzheimer's Disease model rats. Physiology and Pharmacology, 2021, .	0.1	1
159	Regulated cell death: discovery, features and implications for neurodegenerative diseases. Cell Communication and Signaling, 2021, 19, 120.	2.7	48
160	Tau aggregation and its relation to selected forms of neuronal cell death. Essays in Biochemistry, 2021, 65, 847-857.	2.1	7
161	The role of necroptosis in disease and treatment. MedComm, 2021, 2, 730-755.	3.1	27
162	Radiosynthesis and characterization of a carbon-11 PET tracer for receptor-interacting protein kinase 1. Nuclear Medicine and Biology, 2022, 110-111, 18-27.	0.3	1
164	Clinical Research Investigating Alzheimerâ€™s Disease in China: Current Status and Future Perspectives Toward Prevention. journal of prevention of Alzheimer's disease, The, 0, , 1.	1.5	2
166	Itâ€™s All in the PAN: Crosstalk, Plasticity, Redundancies, Switches, and Interconnectedness Encompassed by PANoptosis Underlying the Totality of Cell Death-Associated Biological Effects. Cells, 2022, 11, 1495.	1.8	37
167	Catching a killer: Mechanisms of programmed cell death and immune activation in Amyotrophic Lateral Sclerosis. Immunological Reviews, 2022, 311, 130-150.	2.8	9

#	Article	IF	Citations
168	Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress. European Journal of Medicinal Chemistry, 2022, 238, 114464.	2.6	41
169	Discovery, Optimization and Evaluation of Isothiazolo[5,4-B]Pyridine Derivatives as RIPK1 Inhibitors with Potent in Vivo Anti-SIRS Activity. SSRN Electronic Journal, 0, , .	0.4	0
170	Targeting Necroptosis as a Promising Therapy for Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2022, 13, 1697-1713.	1.7	13
171	Microglia in Alzheimerâ€™s Disease: A Favorable Cellular Target to Ameliorate Alzheimerâ€™s Pathogenesis. Mediators of Inflammation, 2022, 2022, 1-17.	1.4	3
172	Safety, pharmacokinetics and target engagement of novel <scp>RIPK1</scp> inhibitor <scp>SAR443060</scp> (<scp>DNL747</scp>) for neurodegenerative disorders: Randomized, <scp>placeboâ€controlled</scp>, <scp>doubleâ€blind</scp> phase I/Ib studies in healthy subjects and patients. Clinical and Translational Science, 2022, 15, 2010-2023.	1.5	31
173	Nuclear RIPK1 promotes chromatin remodeling to mediate inflammatory response. Cell Research, 2022, 32, 621-637.	5.7	18
174	Microglial mTOR Activation Upregulates Trem2 and Enhances Î²-Amyloid Plaque Clearance in the 5XFAD Alzheimer's Disease Model. Journal of Neuroscience, 2022, 42, 5294-5313.	1.7	34
175	Knowledge Mapping of Necroptosis From 2012 to 2021: A Bibliometric Analysis. Frontiers in Immunology, 0, 13, .	2.2	27
176	25-Hydroxycholesterol as a Signaling Molecule of the Nervous System. Biochemistry (Moscow), 2022, 87, 524-537.	0.7	10
177	Innate Immune Cell Death in Neuroinflammation and Alzheimerâ€™s Disease. Cells, 2022, 11, 1885.	1.8	49
178	RIP kinases and necroptosis in aging and aging-related diseases. , 2022, 1, 2-20.		8
179	Necroptosis and Neuroinflammation in Retinal Degeneration. Frontiers in Neuroscience, 0, 16, .	1.4	5
180	A BAF-fling connection to RIPK1. Cell Research, 2022, 32, 709-710.	5.7	2
181	NeÑroptosis and the experience of its targeted modulation in the context of personalized medicine. , 2022, 2, 33-45.		1
182	Identification of risk genes for Alzheimerâ€™s disease by gene embedding. Cell Genomics, 2022, 2, 100162.	3.0	12
183	Discovery, optimization and evaluation of isothiazolo[5,4-b]pyridine derivatives as RIPK1 inhibitors with potent in vivo anti-SIRS activity. Bioorganic Chemistry, 2022, 129, 106051.	2.0	2
184	Pathogenesis, therapeutic strategies and biomarker development based on â€œomicsâ€•analysis related to microglia in Alzheimerâ€™s disease. Journal of Neuroinflammation, 2022, 19, .	3.1	12
185	Comparison of Cerebral Cortex Transcriptome Profiles in Ischemic Stroke and Alzheimerâ€™s Disease Models. Clinical Nutrition Research, 2022, 11, 159.	0.5	1

#	Article	IF	Citations
186	Alzheimerâ€™s Disease and Inflammaging. Brain Sciences, 2022, 12, 1237.	1.1	26
187	The Effect of Ghrelin on Apoptosis, Necroptosis and Autophagy Programmed Cell Death Pathways in the Hippocampal Neurons of Amyloid-Î² 1â€“42-Induced Rat Model of Alzheimerâ€™s Disease. International Journal of Peptide Research and Therapeutics, 2022, 28, .	0.9	7
188	Advances in RIPK1 kinase inhibitors. Frontiers in Pharmacology, 0, 13, .	1.6	13
189	Bibliometric analysis of publications on necroptosis from 2001 to 2021. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	1
190	Necroptosis Contributes to LPS-Induced Activation of the Hypothalamic-Pituitary-Adrenal Axis in a Piglet Model. International Journal of Molecular Sciences, 2022, 23, 11218.	1.8	1
191	Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimerâ€™s mouse model. Frontiers in Aging Neuroscience, 0, 14, .	1.7	8
193	The relationship among amyloid-Î² deposition, sphingomyelin level, and the expression and function of P-glycoprotein in Alzheimerâ€™s disease pathological process. Neural Regeneration Research, 2023, 18, 1300.	1.6	0
194	Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2022, 65, 14957-14969.	2.9	10
195	Necroptosis: A Pathogenic Negotiator in Human Diseases. International Journal of Molecular Sciences, 2022, 23, 12714.	1.8	22
196	Recent Progress in Research on Mechanisms of Action of Natural Products against Alzheimerâ€™s Disease: Dietary Plant Polyphenols. International Journal of Molecular Sciences, 2022, 23, 13886.	1.8	6
197	Microglial Dysfunction in Neurodegenerative Diseases via RIPK1 and ROS. Antioxidants, 2022, 11, 2201.	2.2	3
198	Small-Molecule Receptor-Interacting Protein 1 (RIP1) Inhibitors as Therapeutic Agents for Multifaceted Diseases: Current Medicinal Chemistry Insights and Emerging Opportunities. Journal of Medicinal Chemistry, 2022, 65, 14971-14999.	2.9	8
199	Necroptosis Blockade Potentiates the Neuroprotective Effect of Hypothermia in Neonatal Hypoxic-Ischemic Encephalopathy. Biomedicines, 2022, 10, 2913.	1.4	2
201	Necroptosis and Alzheimerâ€™s Disease: Pathogenic Mechanisms and Therapeutic Opportunities. Journal of Alzheimer's Disease, 2023, 94, S367-S386.	1.2	7
202	Construction of lncRNA-ceRNA Networks to Reveal the Potential Role of Lfng/Notch1 Signaling Pathway in Alzheimerâ€™s Disease. Current Alzheimer Research, 2022, 19, 772-784.	0.7	2
203	Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 2239-2252.	0.4	25
204	Alzheimer's diseaseâ€associated <scp>R47H TREM2</scp> increases, but wildâ€type <scp>TREM2</scp> decreases, microglial phagocytosis of synaptosomes and neuronal loss. Glia, 2023, 71, 974-990.	2.5	8
205	Beyond the classical amyloid hypothesis in Alzheimer's disease: Molecular insights into current concepts of pathogenesis, therapeutic targets, and study models. WIREs Mechanisms of Disease, 2023, 15, .	1.5	3

#	Article	IF	Citations
206	Omics approaches to better understand the molecular mechanism of necroptosis and their translational implications. Molecular Omics, 0, , .	1.4	0
207	A new perspective on the potential application of RIPK1 in the treatment of sepsis. Immunotherapy, 2023, 15, 43-56.	1.0	4
208	Role of the caspase-8/RIPK3 axis in Alzheimerâ€™s disease pathogenesis and AÎ²-induced NLRP3 inflammasome activation. JCI Insight, 2023, 8, .	2.3	12
209	TREM2 signalling as a multifaceted player in brain homoeostasis and a potential target for Alzheimer's disease treatment. European Journal of Neuroscience, 2023, 57, 718-733.	1.2	5
210	RIPK1 Regulates Microglial Activation in Lipopolysaccharide-Induced Neuroinflammation and MPTP-Induced Parkinsonâ€™s Disease Mouse Models. Cells, 2023, 12, 417.	1.8	9
211	Structure-Based Design of Novel Alkynyl Thio-Benzoxazepinone Receptor-Interacting Protein Kinase-1 Inhibitors: Extending the Chemical Space from the Allosteric to ATP Binding Pockets. Journal of Medicinal Chemistry, 2023, 66, 3073-3087.	2.9	3
212	Definition of the contribution of an Osteopontin-producing CD11c ⁺ microglial subset to Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	13
213	Discovery of Sibiriline derivatives as novel receptor-interacting protein kinase 1 inhibitors. European Journal of Medicinal Chemistry, 2023, 250, 115190.	2.6	3
214	Antiâ€oxidative and antiâ€neuroinflammatory role of Necrostatinâ€1s and docosahexaenoic acid in RIPâ€1â€mediated neurotoxicity in MPTPâ€induced Parkinson's disease model. Fundamental and Clinical Pharmacology, 0, , .	1.0	1
215	Targeting RIPK1 kinase for modulating inflammation in human diseases. Frontiers in Immunology, 0, 14, .	2.2	8
216	Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present). Expert Opinion on Therapeutic Patents, 2023, 33, 101-124.	2.4	3
217	Insulinâ€like growth factor 1 ameliorates preâ€eclampsia by inhibiting zinc finger Eâ€box binding homeobox 1 by upâ€regulation of <scp>microRNA</scp>â€183. Journal of Cellular and Molecular Medicine, 2023, 27, 1179-1191.	1.6	2
218	Presequence protease reverses mitochondriaâ€specific amyloidâ€Î²â€induced mitophagy to protect mitochondria. FASEB Journal, 2023, 37, .	0.2	5
231	Roles of RIPK1 as a stress sentinel coordinating cell survival and immunogenic cell death. Nature Reviews Molecular Cell Biology, 2023, 24, 835-852.	16.1	3
234	Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	23
245	RECENT DEVELOPMENTS IN THE DISCOVERY OF BRAIN-PENETRANT RIP1 INHIBITORS. Medicinal Chemistry Reviews, 0, , 83-102.	0.1	0
250	A guide to cell death pathways. Nature Reviews Molecular Cell Biology, 0, , .	16.1	7